Milton Packer Selected Research

dapagliflozin

11/2023	Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status.
1/2023	Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure.
1/2020	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
10/2019	Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
10/2019	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Milton Packer Research Topics

Disease

310	Heart Failure 05/2024 - 06/2002
28	Cardiomyopathies (Cardiomyopathy) 05/2024 - 08/2013
27	Type 2 Diabetes Mellitus (MODY) 03/2024 - 01/2017
24	Atrial Fibrillation 12/2023 - 05/2007
22	Inflammation (Inflammations) 05/2024 - 01/2018
20	Fibrosis (Cirrhosis) 05/2024 - 01/2017
16	Chronic Renal Insufficiency 05/2024 - 12/2004
16	Disease Progression 01/2023 - 08/2013
13	Stroke (Strokes) 04/2024 - 01/2017
13	Hypotension (Low Blood Pressure) 03/2024 - 04/2013
13	Obesity 07/2023 - 01/2018
11	Myocardial Infarction 04/2024 - 12/2003
11	Hypoxia (Hypoxemia) 01/2024 - 01/2020
10	Sudden Death 10/2022 - 07/2002
9	Diabetes Mellitus 11/2023 - 11/2014
9	Polycythemia (Erythrocytosis) 01/2023 - 12/2016
8	Body Weight (Weight, Body) 08/2023 - 01/2017
8	Left Ventricular Dysfunction 01/2020 - 08/2002
7	Iron Deficiencies 05/2024 - 12/2022
6	Heart Diseases (Heart Disease) 10/2023 - 01/2017
6	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 04/2015
5	Chronic Kidney Failure (Chronic Renal Failure) 01/2024 - 01/2020
5	Hyperkalemia 01/2022 - 09/2014
4	Anemia 10/2023 - 01/2023
4	Hypertrophy 10/2023 - 12/2014
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2023 - 01/2021
4	Hypertension (High Blood Pressure) 01/2023 - 02/2004
4	Weight Loss (Weight Reduction) 01/2023 - 12/2016
4	Cardiotoxicity 12/2019 - 12/2016
4	Edema (Dropsy) 10/2019 - 08/2013
3	Kidney Diseases (Kidney Disease) 04/2024 - 01/2023
3	Frailty 12/2023 - 01/2018
3	Vascular Diseases (Vascular Disease) 11/2023 - 01/2021

Drug/Important Bio-Agent (IBA)

77	sacubitril and valsartan sodium hydrate drug combinationIBA 04/2024 - 10/2012
63	empagliflozinIBA 04/2024 - 01/2017
53	Neprilysin (Neutral Endopeptidase)IBA 01/2023 - 08/2002
44	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2023 - 01/2017
40	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2024 - 12/2003
39	Sodium-Glucose Transport ProteinsIBA 04/2024 - 01/2017
36	SodiumIBA 04/2024 - 01/2017
35	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2023 - 10/2012
35	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2023 - 08/2002
34	Enalapril FDA LinkGeneric 01/2023 - 08/2002
31	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 01/2012
25	pro-brain natriuretic peptide (1-76)IBA 10/2023 - 03/2004
23	paragonIBA 03/2024 - 01/2017
22	Natriuretic PeptidesIBA 12/2023 - 07/2014
20	Biomarkers (Surrogate Marker)IBA 05/2024 - 10/2018
17	Valsartan (Vals)FDA Link 03/2024 - 10/2012
16	DiureticsIBA 08/2023 - 07/2002
13	Sirtuin 1IBA 01/2024 - 01/2020
12	Insulin (Novolin)FDA Link 04/2024 - 10/2017
10	Troponin T (Troponin T1)IBA 12/2023 - 11/2014
10	Mineralocorticoid Receptor AntagonistsIBA 11/2022 - 01/2006
10	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 10/2017
10	Carvedilol (Coreg)FDA LinkGeneric 08/2017 - 10/2002
9	IronIBA 05/2024 - 12/2022
9	SymportersIBA 04/2024 - 01/2018
9	Angiotensin Receptor AntagonistsIBA 11/2022 - 06/2014
9	AngiotensinsIBA 09/2022 - 09/2014
9	AdipokinesIBA 01/2021 - 10/2017
9	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2020 - 08/2002
8	Uric Acid (Urate)IBA 01/2024 - 01/2018
8	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2023 - 01/2018
7	CreatinineIBA 04/2024 - 01/2021
7	Hemoglobins (Hemoglobin)IBA 05/2023 - 01/2016
7	Digoxin (Digitek)FDA LinkGeneric 01/2022 - 05/2004
7	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 02/2018
6	AlbuminsIBA 04/2024 - 01/2021
6	PotassiumIBA 11/2022 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2020
5	dapagliflozinIBA 11/2023 - 10/2019
5	Glucagon-Like Peptide 1 (GLP 1)IBA 07/2023 - 01/2018
5	Oxygen (Dioxygen)IBA 04/2023 - 01/2020
5	Erythropoietin FDA Link 04/2023 - 01/2020
5	Vasodilator Agents (Vasodilators)IBA 01/2023 - 11/2002
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 01/2018
5	aliskiren FDA Link 01/2023 - 10/2017
5	AldosteroneIBA 10/2018 - 10/2017
4	Adenosine Triphosphate (ATP)IBA 01/2024 - 12/2022
4	Adenosine Monophosphate (AMP)IBA 01/2024 - 01/2018
4	TOR Serine-Threonine KinasesIBA 01/2024 - 01/2021
4	flosequinanIBA 01/2023 - 11/2002
4	TroponinIBA 01/2023 - 11/2014
4	LeptinIBA 01/2021 - 01/2018
4	Trinitrotoluene (TNT)IBA 01/2021 - 11/2014
4	LipidsIBA 01/2021 - 01/2020
4	Sodium-Hydrogen ExchangersIBA 01/2021 - 01/2017
4	EnzymesIBA 11/2020 - 12/2016
4	Peptides (Polypeptides)IBA 01/2020 - 01/2017
4	ThiazolidinedionesIBA 01/2020 - 01/2018
4	Spironolactone (Aldactone)FDA LinkGeneric 01/2018 - 01/2006
3	Ferritins (Ferritin)IBA 05/2024 - 12/2022
3	HepcidinsIBA 05/2024 - 12/2022
3	Protein Kinases (Protein Kinase)IBA 01/2024 - 01/2020

Therapy/Procedure

75	Therapeutics 05/2024 - 06/2002
9	Catheter Ablation 01/2021 - 01/2018
5	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 01/2019
4	Patient Readmission 01/2023 - 01/2016
4	Cardiac Resynchronization Therapy 01/2022 - 06/2002